The ideal blood pressure (BP) to decrease mortality rates in patients with non-dialysis-dependent chronic kidney disease (CKD) is unclear.
B
lood pressure (BP) is associated with a linearly incremental risk for cardiovascular disease and death in the general population (1) (2) (3) (4) (5) . Hypertension treatment guidelines recommend treating elevated systolic BP (SBP) without consideration of the diastolic BP (DBP) (unless it, too, is elevated) (6) . These recommendations could be problematic in persons with low DBP because excessively low DBP has been correlated with death (7) (8) (9) . These issues are especially important in patients with chronic kidney disease (CKD) because they are more likely to have increased vascular stiffness and atherosclerosis, resulting in higher pulse pressures. In addition, the BP treatment targets in patients with non-dialysis-dependent CKD have been stricter than those in the general population (6, 10) .
Recent guidelines from the Kidney Disease: Improving Global Outcomes initiative advocate for a BP treatment target of less than 140/90 mm Hg in patients with CKD who have no proteinuria and a stricter target of less than 130/80 mm Hg in patients with micro-and macroalbuminuria (11) . These targets emphasize reducing SBP without consideration of the potential clinical effects of low DBP. Guidelines for reducing SBP in patients with albuminuria will probably result in even lower DBP with treatment.
The presence of a J curve for DBP in this case could negate the benefits of lowering SBP (12) , yet very little is known about the DBP that could be regarded as safe in patients with CKD in this context, especially because observational studies examining SBP or DBP separately may be unable to provide sufficient information about the combined effect of the 2 components on clinical outcomes. Studies that have examined the association of SBP and DBP in patients with CKD did not include enough patients to allow for granular examinations of SBP-DBP combinations to inform whether elevated SBP combined with ideal DBP or ideal SBP combined with low DBP is more advantageous for survival.
We examined the association of both SBP and DBP with all-cause mortality in a large national cohort of U.S. veterans with non-dialysis-dependent CKD. We assessed the effect of SBP and DBP on death separately, and we also examined the effects of actual BP (that is, the combination of SBP and DBP at the individual level) to determine which BP is associated with the most optimal outcome.
METHODS

Cohort Definition
The generation of our CKD cohort was previously described (13, 14) . We used all serum creatinine measurements obtained in clinical settings in all U.S. Department of Veterans Affairs (VA) health care facilities between 1 October 2004 and 30 September 2006 from the Decision Support System National Data Extracts Laboratory Results file (a VA-wide database containing select laboratory results obtained in the clinical setting) (15) . Glomerular filtration rates (GFRs) were estimated from serum creatinine measurements and demographic characteristics by the Chronic Kidney Disease Epidemiology Collaboration equation (16) . Using a predefined algorithm, we identified patients with CKD on the basis of a stable estimated GFR (eGFR) and the presence of an elevated spot urinary microalbumincreatinine ratio (UACR) (for those with eGFRs Ն60 mL/ min per 1.73 m 2 ) (17) . The algorithm for cohort definition is shown in Appendix Figure 1 (available at www.annals.org). Of 4 381 049 patients with any available eGFRs, 651 749 had non-dialysis-dependent CKD, available BP measurements, and sufficient follow-up for survival analysis.
Sociodemographic Characteristics, BP, Medication Use, Comorbid Conditions, and Laboratory Measurements Data on patient age, sex, race, and BP were obtained through the VA Corporate Data Warehouse. Information on race was complemented with data obtained from Medicare through the VA-Medicare data merge project (18) .
Information about BP, laboratory, and other followup data were collected from the date of cohort entry until the end of follow-up (death or 30 April 2012). All BPs measured in clinical practice at all VA facilities between 1 October 2004 and 30 April 2012 were recorded and grouped by calendar quarters, and their quarterly averaged values were used for analyses to reduce random variability. We identified exposure to antihypertensive medications and lipid-lowering agents on the basis of VA pharmacy dispensation records (19) . Antihypertensive medications were classified according to their mechanism of action (angiotensin-converting enzyme inhibitors or angiotensinreceptor blockers; ␣-blockers, ␤-blockers, and calciumchannel blockers; and loop and thiazide diuretics). Medication classes used in fewer than 5% of participants (vasodilators, potassium-sparing diuretics, combination antihypertensives, and others) were not recorded. Exposure to each medication category was assessed longitudinally between 1 October 2004 and 30 April 2012 by recording the presence or absence of outpatient dispensations during each calendar quarter.
Data on comorbid conditions were collected from the VA inpatient and outpatient medical SAS data sets (20, 21) using International Classification of Diseases, Ninth Revision, diagnostic and procedure codes and Current Procedural Terminology codes recorded between 1 October 2004 and 30 September 2006. Prevalent coronary artery disease (CAD) was defined as the presence of diagnostic codes for CAD, angina, or myocardial infarction or procedure codes for percutaneous coronary interventions or coronary artery bypass grafting. We calculated the Charlson Comorbidity Index score using the Deyo modification for administrative data sets excluding kidney disease (22) . Data on laboratory variables were collected between 1 October 2004 and 30 April 2012 by using the Decision Support System National Data Extracts Laboratory Results file (15) . To minimize random variability, we grouped all available laboratory values by calendar quarters and used their quarterly averaged values in analyses.
Statistical Analyses
Descriptive analyses were done for baseline characteristics, and skewed variables were log-transformed. Data on race (1.5%), serum cholesterol level (4.4%), and UACR (80%) were missing. Because of the high degree of missingness, UACR was not included in the main multivariable models, and models including it were treated as exploratory analyses. A total of 624 746 patients (95.9% of the study population) had complete data available for the fully adjusted, main multivariable models. Missing values in this model were not imputed because of their relatively small proportion.
The start of follow-up was the date of the first available BP measurement after 1 October 2004. Patients were followed until death or were censored at the date of the last health care or administrative VA encounter, as documented in the Vital Status Files (a registry that contains these dates from all available sources in the VA system).
Context
The optimal blood pressure for adults with chronic kidney disease is unclear.
Contribution
This large study involving U.S. veterans with non-dialysisdependent chronic kidney disease found that systolic blood pressure (SBP) of 130 to 159 mm Hg and diastolic blood pressure (DBP) of 70 to 89 mm Hg were associated with the lowest mortality rates. Veterans with moderately elevated SBP combined with DBP no less than 70 mm Hg had lower mortality rates than those with ideal SBP and DBP less than 70 mm Hg.
Caution
Associations, but not causality, were established.
Implication
Achieving ideal SBP at the expense of lower-than-ideal DBP could be harmful in adults with chronic kidney disease.
-The Editors
Original Research Blood Pressure and Mortality in CKD The sensitivity and specificity of these files, using the U.S. National Death Index as the gold standard, were 98.3% and 99.8%, respectively (23) .
Blood pressure was examined separately for SBP and DBP. Because previous studies suggested a nonlinear association with death for these variables (24, 25) , they were treated as continuous variables and analyzed using restricted cubic splines with 2 knots at the 33rd and 66th percentiles for SBP (126 and 139 mm Hg) and DBP (66 and 76 mm Hg), using the "uvrs" command in Stata (StataCorp, College Station, Texas) (26) . To better characterize the role of actual BP (the combination of SBP and DBP in any person), we first categorized BP according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommendations: normal (SBP Ͻ120 mm Hg and DBP Ͻ80 mm Hg), prehypertension (SBP of 120 to 139 mm Hg or DBP of 80 to 89 mm Hg, whichever is higher), stage 1 hypertension (SBP of 140 to 159 mm Hg or DBP of 90 to 99 mm Hg, whichever is higher), and stage 2 hypertension (SBP Ն160 mm Hg or DBP Ն100 mm Hg, whichever is higher). The JNC 7 categorization is defined by the presence of a high SBP or DBP; hence, these categories may not accurately represent the effects of low SBP or DBP that may be combined with a high counterpart level. To assess associations of actual BP that equally account for the effects of various combinations of high, normal, or low SBP and DBP, we categorized patients by mutually exclusive combinations of 15 SBP categories (Ͻ80 to Ն210 mm Hg in 10 -mm Hg increments) and 10 DBP categories (Ͻ40 to Ն120 mm Hg in 10 -mm Hg increments). Of these 150 possible categories, we examined 96 categories that included at least 500 patients each. ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin-receptor blocker; BMI ϭ body mass index; CHF ϭ chronic heart failure; CKD ϭ chronic kidney disease; DBP ϭ diastolic blood pressure; eGFR ϭ estimated glomerular filtration rate; IQR ϭ interquartile range; SBP ϭ systolic blood pressure; UACR ϭ urinary microalbumincreatinine ratio. The association of BP with all-cause mortality was examined in time-dependent Cox models, with adjustment for potential confounders. Variables were included in multivariable models if they could be considered confounders (27) on the basis of theoretical considerations. Associations were examined sequentially in models with incremental multivariable adjustments: unadjusted (model 1); age, sex, and race (model 2); model 2 plus comorbid conditions (diabetes mellitus, CAD, chronic heart failure [CHF], cerebrovascular disease, and Charlson Comorbidity Index scores) (model 3); model 3 plus medications (angiotensin-converting enzyme inhibitors or angiotensinreceptor blockers; ␣-blockers, ␤-blockers, and calciumchannel blockers; loop and thiazide diuretics; and cholesterol-lowering agents) (model 4); and model 4 plus eGFRs and blood cholesterol levels (model 5). Longitudinal data, such as BP, medications, and laboratory variables, were evaluated as time-dependent variables in Cox models.
We also examined the association of BP with death in subgroups of patients categorized by sociodemographic characteristics, presence or absence of key comorbid conditions, levels of baseline kidney function, presence or absence of microalbuminuria, and use of antihypertensive medications throughout follow-up. Sensitivity analyses were done using only baseline values for BP, laboratory variables, and medication use. Statistical analyses were done using Stata MP, version 11. The study protocol was approved by the Research and Development Committee at the Memphis Veterans Affairs Medical Center, Memphis, Tennessee.
Role of the Funding Source
This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and the U.S. Department of Veterans Affairs. The funding source had no role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.
RESULTS
Baseline characteristics overall and in patients categorized by JNC 7 hypertension categories are shown in Table  1 . The mean age of the cohort at baseline was 73.8 years (SD, 9.7); 87.8% and 9.3% of patients were white and black, respectively; 43.3% had diabetes mellitus; and the mean eGFR was 50. 4 Calculated in time-dependent Cox models using restricted cubic splines, adjusted for age, sex, race, diabetes mellitus, cardiovascular and cerebrovascular disease, chronic heart failure, Charlson Comorbidity Index scores, medication use (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers; ␣-blockers, ␤-blockers, and calciumchannel blockers; loop and thiazide diuretics; and cholesterol-lowering agents), estimated glomerular filtration rates, and blood cholesterol levels. DBP ϭ diastolic blood pressure; SBP ϭ systolic blood pressure.
Original Research Blood Pressure and Mortality in CKD rates even after multivariable adjustment in timedependent analyses (Figure 1 ) and in analyses using only baseline values of all variables (Appendix Figure 2, . When the same associations in predefined subgroups of patients were examined, a similar pattern was present for all subgroups (including patients with and without diabetes mellitus and those with various eGFRs and UACRs), except for younger patients (in whom prehypertension was associated with the lowest mortality rate), patients with CHF (in whom stage 2 hypertension was associated with the lowest mortality rate), and patients who were never treated with antihypertensive medications (in whom prehypertension was associated with the lowest and stage 2 hypertension with the highest mortality rates) (Figure 2) . Table 3 shows the unadjusted and multivariableadjusted hazard ratios associated with 96 mutually exclusive combinations of SBP and DBP categories. In crude and adjusted analyses, BPs of 130 to 139/90 to 99 mm Hg and 130 to 159/70 to 89 mm Hg, respectively, were associated with the lowest mortality rates. Combinations of lower SBP and DBP (that is, comparing cells diagonally in Table 3 ) were associated with relatively lower mortality rates only if the lower DBP component was greater than approximately 70 mm Hg. Below this DBP, lower BP was associated with higher mortality rates and SBP less than 120 mm Hg was associated with higher mortality rates regardless of the accompanying DBP.
DISCUSSION
In this investigation of the association of SBP-DBP combinations with all-cause mortality in a national cohort of U.S. veterans with CKD, we found that categories of lower SBP-DBP combinations are associated with lower mortality rates only as long as the DBP component remains greater than approximately 70 mm Hg. We also found that patients with BP in the range of 130 to 159/70 to 89 mm Hg had the lowest mortality rates. Patients who may be considered to have "ideal" BP (Ͻ130/80 mm Hg) had increased mortality rates because of the inclusion of persons with low SBP and DBP. Patients with stage 1 hypertension actually had the lowest mortality rates. These associations were consistent in patients with or without diabetes mellitus and in those with or without microalbuminuria.
The association of lower BP with increased mortality rates has been previously described in patients receiving dialysis (7, 28 -32) . A post hoc analysis of the Irbesartan Diabetic Nephropathy Trial (33) and 2 smaller singlecenter studies (24, 25) in patients with non-dialysisdependent CKD have described J-shaped associations of BP with mortality. Similar J-curve phenomena have been described in older adults (34) and patients with preexisting CAD (35, 36) . Of interest, low DBP has recently also been shown to be a risk factor for end-stage renal disease (37) . Although these studies showed the relationship between low DBP and survival, they did not examine the large group of patients with both high SBP and low DBP. The critical role of low DBP in limiting the benefits of treating elevated SBP was shown in a post hoc analysis of the Systolic Hypertension in the Elderly Program, in which an achieved DBP below 60 mm Hg was associated with increased risk for stroke (12) . A consistent J curve for cardiac events and DBP was also apparent in a meta-analysis of antihypertensive trials (38) . To the best of our knowledge (after a structured MEDLINE search), our study is the first to examine the mortality risk associated with discrete combinations of granular SBP-DBP categories. Current treatment paradigms primarily emphasize the higher of the 2 components of BP (SBP and DBP), based on the assumption that only elevated BP is deleterious. Under circumstances when this assumption may not hold (such as in the case of our study population), such categorization ignores the potential negative effects of low SBP or DBP that are linked with their normal or elevated counterparts.
An especially problematic BP pattern is where elevated SBP combines with low DBP, which is common in patients with CKD (39, 40) . Aside from the recognition that the high pulse pressure in this BP pattern is associated with increased mortality rates (7-9), a particularly vexing practical issue is to determine whether lowering the BP in such persons is beneficial by achieving SBP associated with a lower mortality rate or whether it is detrimental by concomitantly inducing an even lower DBP that is associated with higher mortality rates (12) . Nearly one third (32.5%) of the patients in our cohort had SBP greater than 140 mm The group with systolic blood pressure Ͻ120 mm Hg and diastolic blood pressure Ͻ80 mm Hg served as reference. Estimates are from time-dependent Cox models adjusted for age, sex, race, diabetes mellitus, cardiovascular and cerebrovascular disease, chronic heart failure, Charlson Comorbidity Index scores, medication use (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers; ␣-blockers, ␤-blockers, and calcium-channel blockers; loop and thiazide diuretics; and cholesterol-lowering agents), eGFRs, and blood cholesterol levels. CAD ϭ coronary artery disease; CHF ϭ chronic heart failure; eGFR ϭ estimated glomerular filtration rate; HTN ϭ hypertension; UACR ϭ urinary microalbumin-creatinine ratio.
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Hg and DBP less than 70 mm Hg at some point during the observation period. Our granular analyses of BP categories indicated that categories of lower SBP-DBP combinations are associated with lower mortality rates only as long as the DBP component remains greater than approximately 70 mm Hg. These data may indicate that lowering SBP toward the strict limits recommended by current guidelines (SBP Ͻ130 mm Hg or even lower in patients with CKD [6, 10, 11] ) at the expense of lowering DBP to less than approximately 70 mm Hg may be deleterious, but the observational nature of these results limits their interpretability. Therefore, randomized trials are needed to clarify the optimal BP treatment goals in patients with CKD. In the general population with hypertension, trials have demonstrated reduction in cardiovascular events with goals of SBP less than 150 mm Hg or DBP less than 90 mm Hg. On the other hand, a recent large clinical trial of strict BP control in high-risk patients with diabetes mellitus failed to show a reduction in cardiovascular outcomes (41, 42) , and 3 trials in CKD failed to prove that substantially lower BP goals (consistent with Ͻ130/80 mm Hg) substantially reduce major renal outcomes (43) (44) (45) . The National Institutes of Health-sponsored Systolic Blood Pressure Intervention Trial (ClinicalTrials.gov: NCT01206062; www .sprinttrial.org) has been initiated to examine whether an SBP goal less than 120 mm Hg will reduce cardiovascular The J-shaped association of BP with outcomes could be due to compromised blood flow to vital organs (especially low DBP compromising coronary perfusion) or due to confounding by the presence of stiff arteries or the high burden of comorbid conditions (for example, CHF [46] ) that is characteristic of populations with this association pattern. All 3 mechanisms could possibly play roles in the associations seen in our study. Our results suggest that further analyses should be done in BP treatment trials to determine whether active intervention improves survival in persons with low DBP.
Our study is notable for its large size and representativeness of the U.S. veteran population, but it also needs to be interpreted with the recognition of its shortcomings. Because this was an observational study, only associations but no causal relationships can be established from it. Specifically, we cannot conclude that the mortality risk associated with various BPs in our study is equal to the risk imparted by the same BPs when they occur as a result of antihypertensive interventions in clinical practice. Our cohort consisted of U.S. veterans who were almost exclusively men; hence, our findings may not apply to women or the general population. We tried to account for several poten- tial confounding risk factors, but residual confounders could remain. We have explored the role of microalbuminuria in the associations between BP and mortality, but because of the relatively low proportion of patients with available UACR measurements in our cohort, we regard these results as exploratory, and they would need to be confirmed in other studies. We used time-dependent analyses to account for temporal changes in BP and various confounders, such as medication use and kidney function. Longitudinal changes in BP and kidney function could be both causes and consequences of each other, which are difficult to discern using standard analytic techniques. Nevertheless, kidney function did not seem to modify the association of BP with death in any of the models, including those using exclusively baseline data. Because the BPs reported in usual clinical settings, including VA clinics (47) , are often overestimated by 5 to 10 mm Hg compared with research-quality BP measurements, it is possible that the BP ranges we report would be lower if BP was measured more accurately. We describe a J-shaped association between SBP and DBP and all-cause mortality in patients with non-dialysisdependent CKD. The combination of low SBP and low DBP is associated with the highest mortality rates in this population. In addition, DBP less than approximately 70 mm Hg seems to confer increased mortality rates even in patients with ideal SBP. Clinical trials are needed to inform us about the ideal BP target for antihypertensive therapy in patients with CKD. Until such trials become available, low BP should be regarded as potentially deleterious in this patient population, and we suggest caution in lowering BP to less than what has been demonstrated as beneficial in randomized, controlled trials. Original Research Blood Pressure and Mortality in CKD
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